ストックスクリーナーアプリを入手
0.8476
1.36%
-0.0124
アフターアワーズ：
.84
-0.0076
-0.90%
Clearside Biomedical Inc (CLSD) 最新ニュース
Clearside Biomedical at The Citizens Conference: Strategic Trial Insights By Investing.com - Investing.com India
Clearside Biomedical at The Citizens Conference: Strategic Trial Insights - Investing.com Australia
Clearside Biomedical Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $726,000 Position in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical to Participate in a Fireside Chat at the Ci - GuruFocus
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference - GlobeNewswire
Clearside Biomedical Showcases Revolutionary Eye Treatment Platform at Major Healthcare Conference - Stock Titan
Clearside Biomedical (NASDAQ:CLSD) Raised to “Hold” at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
JMP maintains $5 price target on Clearside Biomedical stock By Investing.com - Investing.com Canada
Form DEFA14A Clearside Biomedical, - StreetInsider
CLSD Stock Sees Surge of Approximately 14.80% in Last Five Days - knoxdaily.com
Clearside Biomedical’s (CLSD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Clearside Biomedical stock hits 52-week low at $0.77 - Investing.com
Clearside Biomedical at Needham Conference: Strategic Developments in Retinal Therapies - Investing.com Canada
HC Wainwright Analysts Lift Earnings Estimates for CLSD - Defense World
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Strategic Updates Expected: Clearside Biomedical CEO Takes Stage at Major Healthcare Conference - Stock Titan
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge - Investing.com Australia
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge By Investing.com - Investing.com South Africa
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD - MSN
Clearside Biomedical (NASDAQ:CLSD) Earns “Buy” Rating from Chardan Capital - Defense World
Needham & Company LLC Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock Price - Defense World
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Yahoo
JMP reiterates Clearside Biomedical stock with $5 target By Investing.com - Investing.com Canada
Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Clearside Biomedical buy rating, $8 target By Investing.com - Investing.com UK
Clearside Biomedical (CLSD) Prepares for Phase 3 Trials, Seeks F - GuruFocus
Clearside Biomedical Reports Net Loss for Fourth Quarter and Full Year 2024 - VisionMonday.com
Clearside Biomedical Reports 2024 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast - Investing.com India
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings: EPS Matches Es - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Clearside Biomedical Reports 2024 Financial Results and Updates - TipRanks
Clearside Biomedical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Clearside Biomedical earnings matched, revenue topped estimates - Investing.com
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial - Stock Titan
Exploring Clearside Biomedical's Earnings Expectations - Benzinga
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting - The Manila Times
Clearside Biomedical Announces Six Abstracts Accepted for - GlobeNewswire
Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 - Stock Titan
Clearside Biomedical Presents Comparative Data on CLS-AX for Wet AMD at 2025 Wet AMD & Diabetic Eye Disease Summit - Nasdaq
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet - GlobeNewswire
Clearside's Revolutionary Eye Treatment Platform Targets $12B Wet AMD Market After FDA Green Light - StockTitan
1.33%
2.13%
大文字化:
|
ボリューム (24 時間):